BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Feeling Blue: bluebird bio Cuts Staff by 30%, Prepares for FDA Decision

  Following the ongoing trend in the pharmaceutical industry, approximately 30% of bluebird’s staff will be let go in an effort to reduce operational costs to under $340 million by the end of 2022.

  April 5, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Drug Development

  Theravance Narrows Focus to Multiple System Atrophy Subset Following Mixed Results from the Ampreloxetine Study

  Theravance Biopharma announced mixed results from a study evaluating the use of ampreloxetine to reduce symptomatic neurogenic orthostatis hypotension (nOH).

  April 5, 2022

   · 

  3 min read

   · 

  Jazmine Colatriano M.S.
• 

  Business

  5AM Ventures Pumps Another $750 Million into Life Sciences Industry

  With the close of these two funds, Andrew Schwab, managing partner at 5AM Ventures, said the firm has raised more than $2.2 billion to invest in the life sciences industry.

  April 5, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Imara Left Reassessing After Sickle Cell and Beta-Thalassemia Trials Disappoint

  Imara stock plunged 40% after announcing the failure of Phase II sickle cell and beta-thalassemia trials and plans to discontinue development.

  April 5, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  With mRNA Advancing, Bancel Tells Friends “Don’t Die” in Next 10 Years

  Moderna’s CEO Stéphane Bancel spoke at the Boston College Chief Executives Club on Monday and recapped the laundry list of vaccines and treatments the company plans to develop.

  April 5, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Merck Sets $10 Billion Target for Cardiovascular Pipeline by Mid-2030

  This morning, Merck hosted a cardiovascular investment event where it touted the advances it’s made in its pipeline, which includes a portfolio that has tripled in size over the past year.

  April 5, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  Celeris Reels in Another Big Partner in Boehringer Ingelheim

  Celeris Therapeutics and Boehringer Ingelheim (BI) have announced they are entering into a collaboration to develop next-generation targeted protein degraders.

  April 5, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Career Advice

  How and Why Employees with Disabilities Can Ask for Accommodations

  Requesting disability accommodations is vital for your success in the workplace. You can find out everything about how to ask for accommodations in our guide.

  April 5, 2022

   · 

  4 min read

   · 

  Franklin Carpenter
• 

  Drug Development

  Wave ALS Update Delights Industry Observers, Investors

  The company’s shares rose by 29.6% on NASDAQ shortly after the announcement.

  April 5, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Policy

  COVID-19 Update: Senate Agrees to $10B in Funding, Moderna CEO Talks Boosters

  Stephane Bancel, the chief executive of Moderna, has likened the need for booster vaccine doses to the way Apple releases new smartphones every year.

  April 5, 2022

   · 

  4 min read

   · 

  Vanessa Doctor, RN